LENA BIOSCIENCES, INC.
Atlanta, GA · Medtech · Private
Perfused Organ Panel, an organ-on-a-chip device with proprietary liquid breathing technology for in vitro toxicity screening of animal-derived organ cultures
lenabio.com →- Grants
- $7.0M
- 11 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · SBIR Phase I: Clinical-Trials-on-a-Chip | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Tools for drug efficacy studies in perfused tissue models | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Tools for drug efficacy studies in perfused tissue models | $1,445,834 | |
| Federal grant | Department of Health and Human Services · Phase II · Tools for drug efficacy studies in perfused tissue models | $721,610 | |
| Federal grant | Department of Health and Human Services · Phase I · Perfused organ panel as an animal surrogate for chemical toxicity testing | $252,124 | |
| Federal grant | Department of Health and Human Services · Phase I · A microphysiological system with a synthetic hemoglobin, Blood Substitute, for mechanistic assessment of drug-induced liver injury | $299,948 | |
| Federal grant | Department of Health and Human Services · Phase I · A microphysiological system with a synthetic hemoglobin, Blood Substitute, for mechanistic assessment of drug-induced liver injury | $78,873 | |
| Federal grant | Department of Health and Human Services · Phase II · Perfused organ panel as an animal surrogate for chemical toxicity testing | $881,176 | |
| Federal grant | Department of Health and Human Services · Phase II · Perfused organ panel as an animal surrogate for chemical toxicity testing | $922,650 | |
| Federal grant | Department of Health and Human Services · Phase II · An integrated MPS platform with "virtual humans" for chemical toxicity testing | $900,804 | |
| Federal grant | Department of Health and Human Services · Phase II · An integrated MPS platform with "virtual humans" for chemical toxicity testing | $1,060,260 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2264 | ORTHOMECHANICA, INC. | — | — |
| 2265 | Telo Genomics Corp. | — | $98K |
| 2266 | BIACURE THERAPIES, INC. | — | — |
| 2267 | LENA BIOSCIENCES, INC. | — | — |
| 2268 | Forsagen LLC | — | — |
| 2269 | NANOINNOVATIONS, LLC | — | — |
| 2270 | SILICON BIODEVICES, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.